Corresponding author:Jacqueline Sidman, The Sidman Institute, University Tower, 4199 Campus Drive, Suite 550, Irvine, California, 92612, USA
Received: July 21, 2017; Published: August 07, 2017
To view the Full Article Peer-reviewed Article PDF
The goal of this pilot study was to evaluate psychometric testing to establish objective assessments for treating depression and co-morbid anxiety. Clients of The Sidman Institute were asked to take the BDI-II and BAI before and after three therapy sessions. Short-Term Sidman Hypnotherapy (STSH), independent of antidepressants, resulted in significant improvement by Wilcoxon analysis of BDI-II (Z=3.264, p=0.0011) and BAI (Z=3.233, p=0.0013) with large effect sizes (>0.9). Rumination-associated symptoms decreased significantly, and retrospective followup with previous clients indicated no relapse from one to three years post therapy, further indicating treatment effectiveness.